Pipeline
Therapies that Target the INNATE IMMUNE Response
| DN-TNF Platform | Disease Field | Pre-clinical | Phase I | Phase II (POC) | Pivotal |
|---|---|---|---|---|---|
Mild Alzheimer’s Disease CNS
XPRO™ |
Mild AD | ||||
|
MCI
XPRO™ |
Mild Cognitive Impairment | ||||
|
Treatment Resistant Depression
XPRO™ |
Treatment Resistant Depression |
| NK-Priming Platform | Disease Field | Pre-clinical | Phase I | Phase II (POC) | Pivotal |
|---|---|---|---|---|---|
Inmune Bio for High-Risk MDS
INKmune™ |
Myelodysplastic Syndrome ONCOLOGY |
||||
Inmune Bio for High-Risk MDS
INKmune™ |
Ovarian Cancer |
INKmune for treatment of ovarian cancer Phase I trial begins after resolutions of pandemic